March 30 Update: New Information on Diagnostic Testing for SARS-CoV-2
March 31, 2020
Thank you for your interest in development of diagnostics for SARS-CoV-2. On March 30, 2020, the FDA updated the frequently asked questions on diagnostic testing to include new and updated information on:
- When FDA authorizes a SARS-CoV-2 test for use at the point of care, does that mean it is CLIA waived?
- I am developing a COVID-19 assay that is a modification of a previously EUA authorized COVID-19 assay. Do I need to start from scratch with my validation or can I validate my test with a bridging study?
Recent News
- BioUtah Member Appreciation BBQ 2026 Recap
- Epitel Adds Proven Medtech Leader James Reinstein to Board As Company Enters Next Stage of Growth
- Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
- CLENE ANNOUNCES $4 MILLION REGISTERED DIRECT OFFERING
- Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
- Myriad Genetics Appoints Vishal Sikri Executive Vice President – Commercial
